Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin

[1]  J. Ursing,et al.  Phenotypic characteristics of thermotolerantCampylobacter from human and animal sources , 1983, Current Microbiology.

[2]  H. Goossens,et al.  A new selective medium for the isolation ofCampylobacter jejuni from human faeces , 1983, European Journal of Clinical Microbiology.

[3]  Andrew B. Ziller.  Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults , 1990 .

[4]  M. Altwegg,et al.  rRNA gene restriction patterns and plasmid analysis as a tool for typing Salmonella enteritidis. , 1990, Research in microbiology.

[5]  J. Reina,et al.  Fluoroquinolone-resistance in thermophilic Campylobacter spp isolated from stools of Spanish patients , 1990, The Lancet.

[6]  Y. Miyake,et al.  In Vitro Susceptibility of Campylobacter jejuni to Rokitamycin , 1990, Antimicrobial Agents and Chemotherapy.

[7]  A. Hirschl,et al.  In vitro susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Austria to erythromycin and ciprofloxacin. , 1990, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[8]  H. Endtz,et al.  Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products , 1990, The Lancet.

[9]  P. Dellamonica,et al.  Diarrhea and Campylobacter infections in patients infected with the human immunodeficiency virus. , 1989, The Journal of infectious diseases.

[10]  J. Penner,et al.  The genus Campylobacter: a decade of progress , 1988, Clinical Microbiology Reviews.

[11]  M. Altwegg,et al.  Problems in identification of Campylobacter jejuni associated with acquisition of resistance to nalidixic acid , 1987, Journal of clinical microbiology.

[12]  C. Gaudreau,et al.  Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents. , 1986, The Journal of antimicrobial chemotherapy.

[13]  A. Lastovica,et al.  Mixed infections with different species and serotypes of Campylobacter. , 1986, The Journal of infectious diseases.

[14]  L. Ng,et al.  Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors , 1985, Antimicrobial Agents and Chemotherapy.

[15]  H. Goossens,et al.  Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens , 1985, Antimicrobial Agents and Chemotherapy.

[16]  M. Blaser,et al.  Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli , 1984, Antimicrobial Agents and Chemotherapy.

[17]  M. Walder.  Susceptibility ofCampylobacter fetus subsp. jejuni toTwenty Antimicrobial Agents , 1979 .

[18]  J. Butzler,et al.  Susceptibility of Campylobacter fetus subsp. jejuni to Twenty-Nine Antimicrobial Agents , 1978, Antimicrobial Agents and Chemotherapy.

[19]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .